CNS EFFECTS OF ANTIHYPERTENSIVE THERAPIES

拟议的研究将扩大和加强我们目前的调查 抗高血压的生理和神经心理后遗症 治疗。使用以实验室为基础的定量评估方法 在我们最初对血压正常的男性进行的研究中开发的，另外两个 建议进行研究以评估非药理学和药理学 男性和女性高血压患者的治疗效果。特别感兴趣的 耐受性良好的降压药，如血管紧张素转换酶 关于睡眠生理指标的抑制剂和亲水性β受体阻滞剂， 认知和知觉运动功能，以及情绪状态。这些影响是 在可能的情况下与心血管、循环、 和新陈代谢功能。我们建议进行第一批研究 在绝经后的女性患者中属于这种类型。最后，这两项研究 建议将包括深入比较药物治疗与 我们开发的非常成功的非药物治疗计划 目前的研究。 研究I将包括一项随机、安慰剂对照的评估 男性高血压病患者随机分组治疗效果观察 几种药理状态(依那普利、阿替洛尔、安慰剂)或 非药物治疗。选定的中枢神经系统参数，包括睡眠、 心血管和代谢功能将在治疗前后进行评估。 每个治疗阶段。研究II是第一个前瞻性的安慰剂-- 女性治疗后生物行为后遗症的对照评价 病人。具体来说，绝经后女性高血压患者将 随机分为心得安、依那普利、安慰剂或非药物组 心理治疗。目前的评估程序将相应地修改为 这项研究。综上所述，这些研究将提供一个深入的 现代抗高血压药物的生物行为后遗症评价 治疗，并将在临床管理中的价值 心血管疾病。

The proposed research will broaden and intensify our current investigation of physiological and neuropsychological sequellae of antihypertensive therapies. Using the laboratory-based, quantitative assessment methodology developed in our initial study with normotensive males, two additional studies are proposed to evaluate nonpharmacological and pharmacological treatment effects in male and female hypertensives. Of particular interest are the effects of well tolerated antihypertensive agents, such as ACE inhibitors and hydrophilic beta blockers on measures of sleep physiology, cognitive and perceptual-motor function, and mood state. These effects are to be related, where possible, to changes in cardiovascular, circulatory, and metabolic function. We are als proposing to conduct the first studies of this type in post-menopausal female patients. Finally, both the studies proposed will include intensive comparisons of pharmacological therapy with the highly successful nonpharmacological treatment program developed in our current research. Study I will consist of a randomized, placebo-controlled evaluation of treatment effects in 64 male hypertensive patients assigned to one of several pharmacological conditions (enalapril, atenolol, placebo) or nonpharmacological treatment. Selected CNS parameters, including sleep, cardiovascular, and metabolic functions will be assessed before and after each treatment phase. Study II is the first prospective, placebo- controlled evaluation of biobehavioral sequellae of treatment in female patients. Specifically, 64 post-menopausal female hypertensives will be randomly assigned to propranolol, enalapril, placebo or nonpharmacological therapy. Current assessment procedures will be modified accordingly for this study. Taken together, these studies will provide an in-depth evaluation of biobehavioral sequellae of current antihypertensive therapies, and will be of value in the clinical management of cardiovascular disease.